12/11/2009

An FDA panel recommended approval of Gilead Sciences' cystic fibrosis drug aztreonam to treat lung infections caused by common Pseudomonas aeruginosa bacteria in CF patients. The advisers found the treatment safe and effective when administered in 75-milligram doses three times daily.

Full Story:
Reuters

Related Summaries